Screener Summaries Updates Institutions Sign In More Updates › Earnings › UNCY Earnings · Jul 2, 2026
Unicycive Therapeutics reported an ending cash balance of approximately $61.4 million as of June 30, 2026, based on… UNCY Unicycive Therapeutics, Inc.
Unicycive Therapeutics reported an ending cash balance of approximately $61.4 million as of June 30, 2026, based on preliminary unaudited second-quarter results. The company operates in the biotechnology industry and develops therapeutic products.
More from Unicycive Therapeutics, Inc. All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
